In last trading session, Astria Therapeutics Inc (NASDAQ:ATXS) saw 0.37 million shares changing hands with its beta currently measuring 0.33. Company’s recent per share price level of $3.96 trading at -$0.03 or -0.75% at ring of the bell on the day assigns it a market valuation of $223.48M. That closing price of ATXS’s stock is at a discount of -226.26% from its 52-week high price of $12.92 and is indicating a premium of 10.1% from its 52-week low price of $3.56. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.58 million shares which gives us an average trading volume of 397.72K if we extend that period to 3-months.
For Astria Therapeutics Inc (ATXS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.58 in the current quarter.
Astria Therapeutics Inc (NASDAQ:ATXS) trade information
Upright in the red during last session for losing -0.75%, in the last five days ATXS remained trading in the red while hitting it’s week-highest on Tuesday, 05/13/25 when the stock touched $3.96 price level, adding 17.5% to its value on the day. Astria Therapeutics Inc’s shares saw a change of -55.70% in year-to-date performance and have moved -6.38% in past 5-day. Astria Therapeutics Inc (NASDAQ:ATXS) showed a performance of -0.50% in past 30-days. Number of shares sold short was 2.8 million shares which calculate 5.84 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22.5 to the stock, which implies a rise of 82.4% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 25. It follows that stock’s current price would drop -405.05% in reaching the projected high whereas dropping to the targeted low would mean a loss of -405.05% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.65% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -34.86% while estimates for its earnings growth in next 5 years are of -10.34%.
Astria Therapeutics Inc (NASDAQ:ATXS)’s Major holders
Insiders are in possession of 0.49% of company’s total shares while institution are holding 104.15 percent of that, with stock having share float percentage of 104.66%. Investors also watch the number of corporate investors in a company very closely, which is 104.15% institutions for Astria Therapeutics Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at ATXS for having 6.49 million shares of worth $59.02 million. And as of 2024-06-30, it was holding 11.4815 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 6.05 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.7187 of outstanding shares, having a total worth of $55.1 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Securities Fund-Fidelity Small Cap Growth Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 1.56 shares of worth $6.19 million or 2.77% of the total outstanding shares. The later fund manager was in possession of 1.35 shares on Feb 28, 2025 , making its stake of worth around $5.36 million in the company or a holder of 2.40% of company’s stock.
